Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

Ipsen93 enrolled

Overview

The purpose of this study is to understand how people with neuroendocrine tumors respond to treatment with lanreotide after having received treatment with octreotide.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Neuroendocrine Tumors

Interventions

Data collectionOTHER

This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Males and females age 18 years or older at time of locally advanced or metastatic diagnosis * Patients with a confirmed diagnosis of locally advanced or metastatic Gastroenteropancreatic neuroendocrine tumour (GEP-NET) * Patients who switched treatment from long acting octreotide LAR to lanreotide, where both treatments were received for the treatment of locally advanced or metastatic GEP-NET. i. Treatment with long acting octreotide LAR monotherapy for at least 90-days before treatment with lanreotide monotherapy (rescue SSA# use permitted). ii. Treatment with lanreotide monotherapy for at least 90-days after treatment with long acting octreotide monotherapy (rescue SSA# use permitted) Exclusion Criteria: * Patients with other malignant disease * Patients who participated in a concomitant clinical trial related to treatment of GEP-NET * Patients being treated with a Somatostatin analogue (SSA) in combination with other NET treatments excluding rescue SSA# * Patients who received other primary treatment (e.g., targeted therapy, chemotherapy) for GEP-NET during the interval between octreotide and lanreotide * Patients with NET familial genetic syndrome (i.e., MEN1)

Locations (8)

Moffitt Cancer Center

Tampa, Florida, United States

Cancer Center of Kansas

Wichita, Kansas, United States

Ochsner Clinic Foundation

New Orleans, Louisiana, United States

Mercy Medical Center

Baltimore, Maryland, United States

Outcomes

Primary Outcomes

Response to treatment

Evaluated as responsive disease (i.e., complete response, partial response), stable disease or progressive disease at the last tumor assessment while on treatment with lanreotide (based on tumor imaging, symptoms, biomarker(s) and/or clinical judgement)